Hospital
Bon Secours-Richmond Community Hospital LLC
Bon Secours-Richmond Community Hospital LLC was paid $57.21M by Medicaid between Jan 2018 and Dec 2024, across 275 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoBON SECOURS-RICHMOND COMMUNITY HOSPITAL LLC
RICHMOND, VA 23223
RICHMOND, VA 23223
33aNPI1366404428assigned 04/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$57.21M
24GClaims1,182,682
24DCodes billed275
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#13 of 80
Median peer was paid$14.69M
This provider vs. median3.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 123,494 | $4.19M | |
| 2019 | 167,179 | $6.88M | |
| 2020 | 147,766 | $6.39M | |
| 2021 | 177,883 | $7.79M | |
| 2022 | 187,315 | $9.03M | |
| 2023 | 207,440 | $11.64M | |
| 2024incomplete | 171,605 | $11.29M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 85,012 | 73,159 | $13.87M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 44,747 | 38,409 | $7.77M |
| J9271 | Injection, pembrolizumab, 1 mg | 8.0% | 1,149 | 761 | $4.57M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.9% | 12,318 | 9,394 | $3.95M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.4% | 16,651 | 14,416 | $3.10M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 17,371 | 15,238 | $2.41M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.5% | 14,678 | 9,026 | $2.00M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.1% | 13,914 | 8,034 | $1.77M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.3% | 13,618 | 10,313 | $1.31M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.2% | 5,260 | 3,324 | $1.24M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 5,871 | 5,191 | $1.18M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 4,794 | 4,283 | $1.13M |
263 more codes
| 96415 | 1.7% | 4,090 | $983K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.7% | 775 | $973K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 24,098 | $750K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 4,708 | $676K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 1.2% | 491 | $664K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 23,728 | $517K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,711 | $500K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,472 | $492K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 440 | $476K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,865 | $417K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,137 | $347K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,370 | $339K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,942 | $314K |
| 96367 | <1% | 3,583 | $297K | |
| G0378 | Hospital observation service, per hour | <1% | 1,370 | $264K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,814 | $256K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 4,069 | $226K |
| J0897 | Injection, denosumab, 1 mg | <1% | 878 | $224K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 2,025 | $207K |
| 96416 | <1% | 1,031 | $196K | |
| 97161 | <1% | 2,280 | $187K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,947 | $186K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 104 | $171K |
| 80053 | Comprehensive metabolic panel | <1% | 47,268 | $164K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,890 | $150K |
| 97116 | <1% | 12,186 | $144K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 16,253 | $128K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 76 | $125K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,316 | $125K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 24,282 | $111K |
| 93971 | <1% | 1,206 | $104K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 892 | $102K |
| 96523 | <1% | 1,709 | $98K | |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 51 | $97K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 987 | $83K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 370 | $68K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 451 | $63K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,796 | $61K |
| 76830 | Ultrasound, transvaginal | <1% | 664 | $61K |
| 10060 | <1% | 458 | $60K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 642 | $55K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 28 | $49K |
| 10061 | <1% | 498 | $47K | |
| 72100 | <1% | 2,813 | $46K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30,236 | $44K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,246 | $43K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,498 | $40K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | <1% | 16 | $40K |
| 73562 | <1% | 4,228 | $39K | |
| 12001 | <1% | 169 | $39K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 9,193 | $37K |
| 91200 | <1% | 480 | $35K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,715 | $34K |
| 36591 | <1% | 2,338 | $34K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 27,843 | $33K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,661 | $33K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 178 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 56,362 | $29K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 832 | $28K |
| 90715 | <1% | 1,432 | $27K | |
| 83880 | <1% | 3,767 | $26K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,327 | $26K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 15 | $24K |
| 73030 | <1% | 2,388 | $24K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 505 | $22K |
| 87040 | <1% | 3,036 | $21K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 26 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 60,487 | $21K |
| 96402 | <1% | 1,035 | $20K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 31 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,677 | $18K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 574 | $18K |
| 72050 | <1% | 946 | $18K | |
| 93017 | <1% | 100 | $17K | |
| 73130 | <1% | 2,701 | $16K | |
| 70486 | <1% | 349 | $16K | |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | <1% | 68 | $15K |
| 76801 | <1% | 533 | $14K | |
| 84484 | <1% | 14,314 | $14K | |
| 85379 | <1% | 2,689 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 13,449 | $14K |
| 73630 | <1% | 2,879 | $13K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 24,347 | $13K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,500 | $11K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 151 | $11K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 379 | $10K |
| 73502 | <1% | 1,174 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,227 | $10K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 10,721 | $9K |
| 29125 | <1% | 44 | $9K | |
| J3262 | Injection, tocilizumab, 1 mg | <1% | 130 | $9K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 20,385 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,161 | $8K |
| 73610 | <1% | 2,535 | $8K | |
| 80047 | <1% | 1,951 | $7K | |
| 93970 | <1% | 38 | $7K | |
| 73110 | <1% | 1,307 | $6K | |
| 83605 | <1% | 3,503 | $6K | |
| 80050 | General health panel | <1% | 1,194 | $6K |
| 12002 | <1% | 27 | $6K | |
| 81025 | <1% | 27,849 | $5K | |
| 90714 | <1% | 246 | $5K | |
| 96417 | <1% | 3,760 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,295 | $5K |
| 82728 | <1% | 1,657 | $5K | |
| J3490 | Unclassified drugs | <1% | 14,041 | $5K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,402 | $5K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 89 | $5K |
| 99205 | Prolong outpt/office vis | <1% | 26 | $4K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 20 | $4K |
| 36430 | <1% | 47 | $4K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 175 | $4K |
| 70496 | <1% | 13 | $4K | |
| 81001 | <1% | 41,995 | $4K | |
| 71250 | <1% | 67 | $4K | |
| 70498 | <1% | 45 | $4K | |
| 83550 | <1% | 1,545 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,592 | $3K |
| 74018 | <1% | 440 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 874 | $3K |
| 82553 | <1% | 740 | $3K | |
| 83735 | <1% | 8,104 | $3K | |
| 73140 | <1% | 782 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 16,083 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 378 | $3K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $3K |
| 83540 | <1% | 1,726 | $3K | |
| 80069 | <1% | 1,009 | $3K | |
| 96377 | <1% | 457 | $3K | |
| 12011 | <1% | 12 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 15 | $2K |
| 96401 | <1% | 187 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,226 | $2K |
| 97165 | <1% | 15 | $2K | |
| 85027 | <1% | 1,461 | $2K | |
| 84100 | <1% | 2,146 | $2K | |
| 82962 | <1% | 10,745 | $2K | |
| 80179 | <1% | 413 | $2K | |
| 80143 | <1% | 454 | $2K | |
| 86850 | <1% | 1,390 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,203 | $1K |
| 76642 | <1% | 19 | $1K | |
| 85018 | <1% | 1,094 | $1K | |
| 87210 | <1% | 14,139 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,490 | $1K |
| 96368 | <1% | 814 | $1K | |
| 86140 | <1% | 2,067 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,694 | $1K |
| 86900 | <1% | 1,954 | $1K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,317 | $1K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 2,609 | $1K |
| 84702 | <1% | 2,181 | $960.19 | |
| 83690 | <1% | 10,973 | $902.90 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 16 | $886.81 |
| 97542 | <1% | 14 | $877.11 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,837 | $785.55 |
| 80076 | <1% | 377 | $758.54 | |
| 85652 | <1% | 2,202 | $730.31 | |
| 87070 | <1% | 7,579 | $699.66 | |
| 87147 | <1% | 2,907 | $656.09 | |
| 85014 | <1% | 302 | $641.26 | |
| 73080 | <1% | 172 | $607.97 | |
| 82077 | <1% | 3,408 | $596.76 | |
| 86901 | <1% | 1,954 | $586.57 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,455 | $576.77 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,308 | $575.66 |
| 72131 | <1% | 13 | $557.97 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,512 | $556.95 |
| 82550 | <1% | 2,329 | $489.92 | |
| 84703 | <1% | 1,370 | $488.09 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 972 | $473.53 |
| 71101 | <1% | 70 | $467.02 | |
| 72072 | <1% | 81 | $439.34 | |
| 96376 | <1% | 3,141 | $429.51 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,531 | $424.46 |
| 82378 | <1% | 240 | $405.19 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,010 | $399.81 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,150 | $383.90 |
| 85610 | <1% | 1,836 | $361.91 | |
| 87077 | <1% | 3,769 | $359.08 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,675 | $343.11 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,169 | $321.37 |
| 87186 | <1% | 3,844 | $315.20 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 716 | $288.10 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 191 | $276.72 |
| 81003 | <1% | 1,633 | $240.91 | |
| 82607 | <1% | 45 | $197.92 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,614 | $189.26 |
| 96411 | <1% | 1,679 | $187.74 | |
| 80164 | <1% | 15 | $167.47 | |
| 99218 | <1% | 19 | $145.31 | |
| 82533 | <1% | 51 | $141.12 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 776 | $133.56 |
| 36600 | <1% | 229 | $127.21 | |
| 82784 | <1% | 51 | $81.98 | |
| 86704 | <1% | 149 | $75.56 | |
| 74019 | <1% | 13 | $74.65 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,467 | $69.61 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,494 | $67.85 |
| 87807 | <1% | 562 | $64.10 | |
| 86706 | <1% | 103 | $60.89 | |
| 73590 | <1% | 74 | $59.59 | |
| 87340 | <1% | 142 | $54.55 | |
| 84165 | <1% | 28 | $50.72 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 263 | $47.76 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 398 | $44.10 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 776 | $28.13 |
| 82565 | <1% | 18 | $18.01 | |
| 87634 | <1% | 284 | $17.22 | |
| 84439 | <1% | 18 | $16.84 | |
| 80061 | Lipid panel | <1% | 14 | $15.26 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 174 | $13.14 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 154 | $11.65 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 536 | $11.60 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 310 | $10.78 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 70 | $7.67 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 348 | $6.03 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 284 | $5.39 |
| 87088 | <1% | 272 | $4.67 | |
| J2704 | Injection, propofol, 10 mg | <1% | 912 | $4.08 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 19 | $2.21 |
| 85730 | <1% | 87 | $2.19 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 52 | $2.02 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 40 | $1.71 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 85 | $1.10 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 112 | $0.47 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 357 | $0.36 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 242 | $0.00 |
| 94664 | 0% | 203 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 58 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 57 | $0.00 |
| 82272 | 0% | 28 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 83 | $0.00 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 73 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 20 | $0.00 |
| 84145 | 0% | 50 | $0.00 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 0% | 27 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 26 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 21 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 29 | $0.00 |
| A4565 | Slings | 0% | 15 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 12 | $0.00 |
| 82803 | 0% | 85 | $0.00 | |
| 94760 | 0% | 130 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 3,256 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 645 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 566 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 92 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 359 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 38 | $0.00 |
| 87255 | 0% | 53 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 41 | $0.00 |
| J1456 | Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg | 0% | 76 | $0.00 |
| 94762 | 0% | 35 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 30 | $0.00 |
| 86592 | 0% | 16 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 16 | $0.00 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 15 | $0.00 |
| 73090 | 0% | 13 | $0.00 | |
| 72040 | 0% | 16 | $0.00 | |
| 87205 | 0% | 17 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.